CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction

医学 心力衰竭 射血分数 脑啡肽酶 沙库比林 背景(考古学) 缬沙坦 血管紧张素受体 重症监护医学 心脏病学 内科学 地高辛 药理学 血管紧张素II 受体 血压 古生物学 生物化学 化学 生物
作者
Michael McDonald,Sean Virani,Michael Chan,Anique Ducharme,Justin A. Ezekowitz,Nadia Giannetti,George A. Heckman,Jonathan G. Howlett,Sheri L. Koshman,Serge Lepage,Lisa Mielniczuk,Gordon W. Moe,Eileen O’Meara,Elizabeth Swiggum,Mustafa Toma,Shelley Zieroth,Kim B. Anderson,Sharon Bray,Brian Clarke,Alain Cohen‐Solal,Michel D’Astous,Margot K. Davis,Sabe De,Andrew Grant,Adam Grzeslo,Jodi Heshka,Sabina Keen,Simon Kouz,Douglas S. Lee,Frederick A. Masoudi,Robert S. McKelvie,Marie-Claude Parent,Stephanie Poon,Miroslaw Rajda,Abhinav Sharma,Kyla Siatecki,Kate Storm,Bruce Sussex,Harriette G.C. Van Spall,Amelia Yip
出处
期刊:Canadian Journal of Cardiology [Elsevier BV]
卷期号:37 (4): 531-546 被引量:175
标识
DOI:10.1016/j.cjca.2021.01.017
摘要

In this update of the Canadian Cardiovascular Society heart failure (HF) guidelines, we provide comprehensive recommendations and practical tips for the pharmacologic management of patients with HF with reduced ejection fraction (HFrEF). Since the 2017 comprehensive update of the Canadian Cardiovascular Society guidelines for the management of HF, substantial new evidence has emerged that has informed the care of these patients. In particular, we focus on the role of novel pharmacologic therapies for HFrEF including angiotensin receptor-neprilysin inhibitors, sinus node inhibitors, sodium glucose transport 2 inhibitors, and soluble guanylate cyclase stimulators in conjunction with other long established HFrEF therapies. Updated recommendations are also provided in the context of the clinical setting for which each of these agents might be prescribed; the potential value of each therapy is reviewed, where relevant, for chronic HF, new onset HF, and for HF hospitalization. We define a new standard of pharmacologic care for HFrEF that incorporates 4 key therapeutic drug classes as standard therapy for most patients: an angiotensin receptor-neprilysin inhibitor (as first-line therapy or after angiotensin converting enzyme inhibitor/angiotensin receptor blocker titration); a β-blocker; a mineralocorticoid receptor antagonist; and a sodium glucose transport 2 inhibitor. Additionally, many patients with HFrEF will have clinical characteristics for which we recommended other key therapies to improve HF outcomes, including sinus node inhibitors, soluble guanylate cyclase stimulators, hydralazine/nitrates in combination, and/or digoxin. Finally, an approach to management that integrates prioritized pharmacologic with nonpharmacologic and invasive therapies after a diagnosis of HFrEF is highlighted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
和谐曼凝完成签到 ,获得积分10
1秒前
如意竺完成签到,获得积分10
1秒前
fzd完成签到,获得积分10
3秒前
6秒前
livra1058完成签到,获得积分10
7秒前
HAO完成签到,获得积分10
9秒前
震动的沉鱼完成签到 ,获得积分10
10秒前
糕糕发布了新的文献求助40
11秒前
dyk完成签到,获得积分10
11秒前
13秒前
carryxu完成签到,获得积分10
13秒前
卡卡罗特应助谦让小蚂蚁采纳,获得10
13秒前
大个应助缓慢醉卉采纳,获得10
14秒前
lzhgoashore完成签到,获得积分10
14秒前
14秒前
helpme完成签到,获得积分10
14秒前
DLY完成签到,获得积分10
15秒前
16秒前
16秒前
达笙完成签到 ,获得积分10
17秒前
研友_VZG7GZ应助炒鸡小将采纳,获得10
19秒前
闪闪山柳完成签到 ,获得积分10
19秒前
在水一方应助科研通管家采纳,获得10
20秒前
小二郎应助科研通管家采纳,获得10
20秒前
852应助科研通管家采纳,获得10
20秒前
小马甲应助科研通管家采纳,获得10
20秒前
zzz发布了新的文献求助10
20秒前
wumiao_1应助科研通管家采纳,获得10
20秒前
wumiao_1应助科研通管家采纳,获得10
20秒前
在水一方应助科研通管家采纳,获得10
20秒前
传奇3应助科研通管家采纳,获得10
20秒前
20秒前
21秒前
21秒前
21秒前
小蘑菇应助科研通管家采纳,获得10
21秒前
在水一方应助科研通管家采纳,获得10
21秒前
21秒前
21秒前
21秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038426
求助须知:如何正确求助?哪些是违规求助? 3576119
关于积分的说明 11374556
捐赠科研通 3305834
什么是DOI,文献DOI怎么找? 1819339
邀请新用户注册赠送积分活动 892678
科研通“疑难数据库(出版商)”最低求助积分说明 815029